DelveInsight’s, “Peritoneal Cancer Pipeline Insight 2024” report provides comprehensive insights about 55+ companies...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - MOUNTAINTODAY.IN - A La Une - 19/Jun 07:12
STAT Inhibitors Pipeline Outlook 2024: Clinical Trials, FDA, EMA, PMDA Approvals, Therapies, Growth Opportunities, and Companies by DelveInsight
STAT Inhibitors Pipeline STAT Inhibitors Pipeline report provides comprehensive insights about 60+ companies and 60+ pipeline drugs based on STAT Inhibitors pipeline landscape (Albany, USA) DelveInsight’s ‘STAT Inhibitors Pipeline Insight 2024’ report
Articles similaires
Biliary Tumor Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight
mountaintoday.in - 26/Jun 19:24
DelveInsight’s, “Biliary Tumor Pipeline Insight, 2024” report provides comprehensive insights about 50+ companies and...
Hepatic Tumor Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight
mountaintoday.in - 26/Jun 19:28
DelveInsight’s, “Hepatic Tumor Pipeline Insight 2024”report provides comprehensive insights about 75+ companies and 75+...
PD-1 Non-Small Cell Lung Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight
mountaintoday.in - 26/Jun 19:16
DelveInsight’s, “PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Insight 2024” report provides comprehensive...
Advanced Gastric Carcinoma Pipeline 2024 | Jiangsu Hengrui Medicine, BeiGene, CSPC ZhongQi Pharmaceutical Technology, LintonPharm Co., Ltd., Bristol-Myers Squibb, Hanmi Pharmaceuticals
mountaintoday.in - 04/Jul 17:32
DelveInsight’s, “Advanced Gastric Carcinoma Pipeline Insight, 2024,” report provides comprehensive insights about 50+...
Basal Cell Carcinoma Pipeline 2024 | PellePharm, MedC Biopharma Corporation, AiViva BioPharma, MediWound, Kintara Therapeutics, IO Biotech, Sirnaomics, Aresus Pharma
mountaintoday.in - 04/Jul 17:48
DelveInsight’s, “Basal Cell Carcinoma Pipeline Insight 2024” report provides comprehensive insights about 25+...
B-Cell Lymphoma Clinical Trials Analysis 2024: FDA Approvals, Pipeline, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight
mountaintoday.in - 05/Jul 07:12
B-Cell Lymphoma Pipeline (Albany, United States) As per DelveInsight’s assessment, globally, B-Cell Lymphoma pipeline constitutes 160+ key companies...
Advanced Hepatocellular Carcinoma Pipeline 2024 | CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, Akesobio, BeiGene
mountaintoday.in - 04/Jul 17:44
DelveInsight’s, “Advanced Hepatocellular Carcinoma Pipeline Insight 2024” report provides comprehensive insights...
Advanced Merkel Cell Carcinoma Pipeline 2024 | Xencor, Inc., Incyte Corporation, Millennium Pharmaceuticals, Inc., Exelixis, Bristol-Myers Squibb, bluebird bio, Affini-T Therapeutics
mountaintoday.in - 04/Jul 18:08
DelveInsight’s, “Advanced Merkel cell carcinoma Pipeline Insight 2024” report provides comprehensive insights...
Clostridium Difficile Infections Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight
mountaintoday.in - 28/Jun 16:52
Clostridium Difficile Infections Pipeline Clostridium Difficile Infections companies are Vedanta Biosciences, Adiso Therapeutics, Finch Therapeutics...
Les derniers communiqués
-
Aucun élément